Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma
Enrolling By Invitation
18 years - 99 years
All
Phase
2
6 participants needed
1 Location
Brief description of study
A trial, evaluating molecularly selected, immune-based combination therapy in maintenance treatments for advanced cholangiocarcinoma, selecting patients on the homologous recombination deficient (HRD) signature.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: cholangiocarcinoma
-
Age: 18 years - 99 years
-
Gender: All
Male and Female, Age 18 or older, with histological or cytological documentation of metastatic adenocarcinoma
Updated on
04 Aug 2024.
Study ID: 849941
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
